MDACC Study No:2010-0228 ( NCT No: NCT01022996)
Title:An open-label, single-arm phase II study of everolimus
(RAD001) in patients with relapsed/refractory classical
Hodgkin lymphoma
Principal Investigator:Michelle A. Fanale
Treatment Agent:Everolimus; RAD001
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if everolimus can help to
control Hodgkin lymphoma. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Everolimus
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults